Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1
Vince S. C. Yeh(Abbott (United Kingdom)), Andrew J. Souers(AbbVie (United States)), Terkel Hansen(AbbVie (United States)), David W. A. Beno(Abbott Fund), Russel C. Klix(Abbott Fund), Gang Zhao(Sichuan University), Kennan C. Marsh(AbbVie (United States)), Yau Yi Lau(Pennsylvania State University), Sevan Brodjian(Abbott Fund), Scott W. Mittelstadt(Abbott Fund), Philip R. Kym(AbbVie (United States)), Madhup K. Dhaon(Abbott Fund), Eric J. Stoner(Abbott Fund), Andrew S. Judd(AbbVie (United States)), Regina M. Reilly(Abbott (United States)), Michael J. Rozema(Abbott Fund), Andrew King(The Pirbright Institute), Ju Gao(Sichuan University), Steven C. Cullen(Abbott Fund), Brian D. Dayton(AbbVie (United States)), Kelly J. Larson(Abbott Fund), Xili Xin(Abbott Fund), Dan Plata(Abbott Fund), Xiaojun Wang(Academy of Medical Sciences), Christine A. Collins(AbbVie (United States)), Bryan F. Cox(Abbott Fund), Jason A. Segreti(Abbott Fund), Hugh D. Falls(AbbVie (United States)), Michael E. Brune(Abbott Fund), Martin J. Voorbach(AbbVie (United States)), Philip J. Hajduk(Abbott Fund), Nelson Grihalde(Abbott Fund)
Cited by 34
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776